Wolverine Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
– Sell
-3,200
Closed -$46K – 1514
2017
Q4
$46K Sell
3,200
-5,800
-64% -$79.7K ﹤0.01% 1263
2017
Q3
$135K Sell
9,000
-11,700
-57% -$155K ﹤0.01% 1052
2017
Q2
$208K Buy
20,700
+3,100
+18% +$24.9K ﹤0.01% 946
2017
Q1
$125K Buy
+17,600
New +$111K ﹤0.01% 918

Other funds holding FOLD

Wolverine Asset Management's FOLD Position: Q2 2026 in Review

Wolverine Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 125,265 shares — an estimated $1.81M sold.

Wolverine Asset Management first reported a position in FOLD in Q4 2013 and held it in 6 quarters. The position peaked at $1.81M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Wolverine Asset Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 125,265 Amicus Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Wolverine Asset Management first reported a position in Amicus Therapeutics in Q4 2013 and held it in 6 quarters.
  • Wolverine Asset Management's Amicus Therapeutics position peaked at $1.81M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.